We are live on ! Find out more
CELG.RT

Bristol-Myers Squibb Rights
CELG.RT

Fund managers haven’t disclosed any holdings of CELG.RT yet.

CELG.RT Hedge Fund Activity: Q1 2026 in Review

17 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q1 2026, worth a combined $37.9K — up 51% from $25.1K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CELG.RT and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $1.96K. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.01K sold.

  • 17 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q1 2026, down from 18 in Q4 2025.
  • Funds reported $37.9K of Bristol-Myers Squibb Rights stock for Q1 2026, up 51% quarter-over-quarter.
  • 1 fund opened new Bristol-Myers Squibb Rights positions in Q1 2026 and 2 closed out, a net change of -1 holder.
  • The largest Bristol-Myers Squibb Rights buyer in Q1 2026 was Two Sigma Securities, an estimated $1.96K added.
  • The largest Bristol-Myers Squibb Rights seller in Q1 2026 was Citadel Advisors, an estimated $2.01K sold.

Based on aggregated 13F filings for Q1 2026.